Abstract: The present invention relates to pharmaceutical compositions comprising etoricoxib and tramadol, or a pharmaceutically acceptable salt thereof, for the treatment of pain, which in addition to offering the possibility of an analgesic effect with a decrease in adverse events due to the reduction of the dose of one or both compounds, presents an improved stability, maintaining the dissolution and bioavailability of the composition to be administered; The composition manages to overcome the technological complexity that lies in having a drug with high sensitivity to light and humidity (tramadol), together with another fat-soluble drug with poor flow and excessive adhesiveness (etoricoxib), in a dispensing media in which their absorption is not affected through a water-free process, without affecting the release of both drugs.

Abstract: A system for processing insulation material is disclosed. The system includes a hopper having an opening for receiving insulation material and an outlet; at least one chopping blade disposed in the hopper for reducing the size of insulation material; an auger disposed in the hopper for conducting insulation material received in the opening to the outlet of the hopper; and a blower having an inlet coupled to the outlet of the hopper and an outlet. The system also includes a plate operatively disposed between the outlet of the hopper and the inlet of the blower. The plate defining a plurality of apertures, where the plate is configured to preferentially admit insulation material below a threshold size into the blower and preferentially reject insulation material above the threshold size for reintroduction to the hopper and contact with at least one of the chopping blades.

Abstract: Techniques are provided for generating and maintaining Precomputed Result Tables (“PRTs”) that are used by a database server to improve performance of SPARQL queries that target an RDF graph set. Each PRT corresponds to a particular pattern, which may be simple-triple, star, or chain. The techniques support the creation of PRTs for chain patterns that contain multiple instances of the same property, and PRTs for star and chain patterns that include reverse properties. Techniques are also described for maintaining such PRTs as Data Manipulation Language (DML) operations make changes to the RDF graph tables that belong to the RDF graph set associated with the PRTs.

Abstract: The present disclosure describe a simple optimized method that allows the combined manufacture of five active substances: cyanocobalamin, pyridoxine, thiamine, pregabalin and celecoxib in a single solid, stable, immediate release pharmaceutical form for pain. The combined use of drugs that act at distinct levels is associated with greater pain relief and, as they can be used at lower doses, with a reduced risk of adverse effects. In this context, the combined use of B vitamins plus pregabalin and celecoxib would be associated with greater analgesic activity through complementary action mechanisms.

Abstract: It is described and claimed a pharmaceutical composition comprising celecoxib and acetaminophen as active ingredients, wherein the pharmaceutical composition is an immediate release coated tablet. The pharmaceutical composition is particularly stable and allows the oral administration in a single dosage unit of two active ingredients. It is further provided a process for manufacturing the pharmaceutical composition, as well as the use of said pharmaceutical composition for the treatment of pain, it provides analgesia and a reduction of adverse effects.

Abstract: A loose fill insulation delivery machine can include a hopper configured to receive loose fill insulation; a counter configured to determine an amount of loose fill insulation used; and a display system configured to determine service part replacement. A method of determining service part replacement in a loose fill insulation delivery machine can include operations for tracking a run time of the insulation blowing machine; determining service part replacement based on tracked run time; and displaying service part replacement information.

Abstract: A photon source for promoting the growth and maturation rate of members of the Plantae and Protista Kingdoms comprises a new luminous power source that provides the full range of light spectra by mimicking sunlight in a sunfleck (dappled) pattern by exciting xenon gas inside of an enclosed glass tube in instantaneous pulsed sequences. The micro-dose pulse penetrates the leaf strata to reach the maximum amount of photon processing pigments, provides the energy required for growth by enhancing photosynthetic plant functions, and significantly reducing production energy consumption. The pulse also allows the plant or Protista's photon processing compounds to process the photosynthesis reaction before the next flash, which allows for optimal use of the energy provided. The pulsed lighting sequences reduce energy consumption by up to 90%, and this makes it an excellent application for solar, wind or other green energy power thus reducing carbon footprint and making it the future of the CEA industry.

Abstract: A catheter for extracting thrombotic material from a head blood vessel. The catheter includes a suction sheath to extract the thrombotic material from a distal side to a proximal side of the catheter; an inflation sheath to feed an inflatable balloon to occlude the blood vessel in an inflated state; a tubular extension extending beyond the distal end of the inflation sheath, the extension being defined such that a distal tip of the extension is placed downstream the ophthalmic segment when the distal end of the inflation sheath is placed upstream the ophthalmic segment. A method for extracting thrombotic material from a head blood vessel is provided as well.

Abstract: Provided herein are multilayer polymeric interlayers comprising ionomers and acoustic damping compositions, and glass laminates made from them, which provide an improved combination of hurricane resistance, acoustic damping properties and, optionally, solar barrier performance.

Abstract: A system for providing a remote computing resource to a user equipment comprises the user equipment and at least one server. The user equipment is configured to receive a user input from an input device of the user equipment and send data identifying the user input to the server, wherein the data identifying the user input is based on data from a hardware driver of the input device. The server is configured to receive the data identifying the user input, cause execution of the remote computing resource based on the data identifying the user input, and send an output of the executed remote computing resource to the user equipment. A user equipment and a server are also provided.

Abstract: A system for monitoring Gastro-intestinal disorders including: a gastro-intestinal probe; at least one sensor configured to measure a parameter of the patient; a processor configured to: determine a first and second values corresponding to a given time interval, wherein the first value is determined based on a measurement of the parameter and the second value is determined based on a measurement of gastro-esophageal content corresponding to the given time interval; and determine a level of gastro-intestinal disorder based on the determined set of pairs of values.

Abstract: A system for monitoring gastro-intestinal disorders including: a gastro-intestinal probe; at least one sensor configured to measure a parameter of the patient; a patient interface configured to receive inputs from the patient; a processor configured to: determine a first and second values corresponding to a given time interval: wherein, if an input from the patient corresponds to the given time interval, the first value is determined based on a measurement of the parameter corresponding to the given time interval and on the input from the patient corresponding to the given time interval, and wherein said second value is determined based on a measurement of gastro-esophageal content corresponding to the given time interval; and determine a level of gastro-intestinal disorder based on the determined set of pairs of values.

Abstract: The invention relates to a nutraceutical formulation of blueberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption. The invention belongs to the field of ophthalmology and has been developed as a coadjuvant for preserving the health of the precorneal film and of the eye surface. This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film.

Abstract: A photon source for promoting the growth and maturation rate of members of the Plantae and Protista Kingdoms comprises a new luminous power source that provides the full range of light spectra by mimicking sunlight in a sunfleck (dappled) pattern by exciting xenon gas inside of an enclosed glass tube in instantaneous pulsed sequences. The micro-dose pulse penetrates the leaf strata to reach the maximum amount of photon processing pigments, provides the energy required for growth by enhancing photosynthetic plant functions, and significantly reducing production energy consumption. The pulse also allows the plant or Protista's photon processing compounds to process the photosynthesis reaction before the next flash, which allows for optimal use of the energy provided. The pulsed lighting sequences reduce energy consumption by up to 90%, and this makes it an excellent application for solar, wind or other green energy power thus reducing carbon footprint and making it the future of the CEA industry.

Abstract: A combination in only one dosage unit the drugs desloratadine and betamethasone, which represents a set of important technological challenges due to the physicochemical properties and the difference in dosage to ensure the obtaining of a stable product for the treatment of allergic and inflammatory processes in a subject.

Abstract: Pharmaceutical compositions of tramadol and pregabalin, or a pharmaceutically acceptable salt thereof, for the treatment of neuropathic pain. Besides offering an analgesic effect and a decrease of adverse events due to the reduced dose of one or both compounds, it has an improved stability, thus maintaining the dissolution and bioavailability of the composition to be administered. The composition manages to overcome the technological difficulty of having two humidity- and light-sensitive drugs in a dispensing medium that does not affect their absorption by means of a water-free process and a light protection coating without affecting the release of both drugs.

Abstract: An improved, immediate-release pharmaceutical composition against respiratory diseases and acute upper respiratory tract infections (IAVRS) with a stable bioavailability and includes an analgesic, such as ibuprofen; an antihistamine, such as loratadine; and one or more excipients, such as suspending agents, solubilizers, co-solvents, sweeteners or flavorings, colorants, preservatives or antimicrobials, and solvents. The manufacturing process of the composition manages to overcome the technological complexity of having both drugs in liquid form while preserving their physicochemical properties.

Abstract: The manufacture of fixed-dose combination drug products to be used as an anti-inflammatory and antineuritic agents for the control and management of pain, particularly moderate to severe intensity acute pain of different etiologies resulting from peripheral neuropathies, low back pain, sciatica, neck pain, radiculitis, post-herpetic neuralgia, spondylitis, carpal tunnel syndrome, fibromyalgia, etc., of different etiologies such as inflammatory, drug, diabetic, alcoholic, or nutritional etiology, etc. These fixed-dose combination drug products contain a therapeutically effective amount of (a) a non-steroidal anti-inflammatory drug (NSAID) or a pharmaceutically acceptable salt thereof, (b) an antineuritic agent or a pharmaceutically acceptable salt thereof, and (c) at least one pharmaceutically acceptable amount of a pharmaceutically acceptable excipient.

Abstract: A photon source for promoting the growth and maturation rate of members of the Plantae and Protista Kingdoms comprises a new luminous power source that provides the full range of light spectra by mimicking sunlight in a sunfleck (dappled) pattern by exciting xenon gas inside of an enclosed glass tube in instantaneous pulsed sequences. The micro-dose pulse penetrates the leaf strata to reach the maximum amount of photon processing pigments, provides the energy required for growth by enhancing photosynthetic plant functions, and significantly reducing production energy consumption. The pulse also allows the plant or Protista's photon processing compounds to process the photosynthesis reaction before the next flash, which allows for optimal use of the energy provided. The pulsed lighting sequences reduce energy consumption by up to 90%, and this makes it an excellent application for solar, wind or other green energy power thus reducing carbon footprint and making it the future of the CEA industry.

Abstract: A combination, in a single dosage form, the active principles, atorvastatin and fenofibrate, which represents a set of important technological challenges due to the physicochemical properties and the difference in dosage to ensure obtaining a stable product in the treatment of hyperlipidemia and the prevention of cardiovascular diseases.